10-Q: REMSLEEP Faces Going Concern Doubt Amid Revenue Plunge

REMSLEEP Holdings, Inc. reports a significant revenue decline and increased liabilities, raising substantial doubt about its ability to continue as a going concern despite new product sales.

Summary

• REMSLEEP Holdings, Inc. reported a net loss of $373,260 for the six months ended June 30, 2025, an improvement from a $478,179 net loss in the prior year period.
• Revenue for the six months ended June 30, 2025, plummeted to $4,824 from $85,475 in the same period last year, reflecting a shift from selling CPAP machines to the new DeltaWave product.
• Cash at the end of the period was $415,975, down from $698,727 as of June 30, 2024.
• The company used $251,368 in cash from operating activities for the six months ended June 30, 2025.
• Total liabilities increased significantly to $401,708 as of June 30, 2025, from $254,994 at December 31, 2024.
• Stockholders' equity (deficit) decreased to $140,006 from $336,703 over the same period.
• The company received FDA 510k approval for its DeltaWave product on July 2, 2024, and began selling it in Q2 2025.
• Development expenses decreased by 88% to $18,700 for the six months ended June 30, 2025, as DeltaWave development was completed.
• The company entered into new convertible promissory notes totaling $204,000 during the six months ended June 30, 2025.
• 15,000,000 warrants were cashless exercised into 11,768,934 common shares on March 13, 2025.
• Convertible debt was converted into 22,460,270 common shares during the six months ended June 30, 2025, and an additional 3,130,434 shares subsequent to period end.

Sentiment

Score: 2

Explanation: The sentiment is highly negative due to a catastrophic decline in revenue, significant increase in liabilities, continued substantial net losses, and explicit disclosure of 'substantial doubt about the company's ability to continue as a going concern.' While development costs decreased and a new product was launched, the financial performance indicates severe operational challenges and a precarious financial position.

Positives

• Net loss decreased to $373,260 for the six months ended June 30, 2025, from $478,179 in the prior year period.
• Cash used in operating activities slightly improved to $251,368 from $265,373 year-over-year.
• The company successfully obtained FDA 510k approval for its DeltaWave product on July 2, 2024, and commenced sales in Q2 2025.
• Development expenses significantly decreased by 88% ($137,320) for the six months ended June 30, 2025, due to the completion of DeltaWave product development and testing.
• Professional fees decreased by 45% ($29,135) for the six months ended June 30, 2025, primarily due to lower legal fees.
• Lease expenses decreased by 48% ($24,433) for the six months ended June 30, 2025, due to a new, less expensive lease in a new location.

Negatives

• Revenue for the six months ended June 30, 2025, was $4,824, a substantial decrease from $85,475 in the same period of 2024.
• Gross margin significantly declined to $4,224 for the six months ended June 30, 2025, from $65,945 in the prior year.
• The company has an accumulated deficit of $15,644,016 as of June 30, 2025.
• Total liabilities increased to $401,708 as of June 30, 2025, from $254,994 at December 31, 2024.
• Stockholders' equity (deficit) decreased to $140,006 as of June 30, 2025, from $336,703 at December 31, 2024.
• Cash balance decreased to $415,975 as of June 30, 2025, from $463,343 at December 31, 2024.
• Disclosure controls and procedures were deemed not effective as of June 30, 2025, due to a lack of segregation of duties.
• The company continues to rely on debt and/or equity financing to fund operations, indicating a lack of self-sufficiency from revenue.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to recurring losses from operations since inception and insufficient cash flow from revenue.
• The company's future success and viability are dependent upon its ability to generate capital financing.
• Failure to generate sufficient revenues or raise additional capital may have a material and adverse effect on the company and its shareholders.
• The company's disclosure controls and procedures were not effective as of June 30, 2025, due to a lack of segregation of duties.
• The company's cash in bank deposit accounts may exceed federally insured limits, with $165,975 above the FDIC's $250,000 coverage limit as of June 30, 2025.
• All accounts receivable balance as of June 30, 2025, is due from one customer, posing a concentration of credit risk.
• Convertible notes payable include terms allowing conversion at a discount (25% or 30%) to the average of the three lowest trades, which can lead to significant dilution for existing shareholders.

Future Outlook

The company plans to continue financing operations through debt and/or equity as needed. Management's plans include obtaining funding from new investors and implementing a strategy to generate sales. The long-term goal is to develop sleep products for Obstructive Sleep Apnea (OSA) and capture 10% of the market within the next 24 months. Clinical trials for the DeltaWave product are planned, pending adequate financing.

Management Comments

• "The Company will continue to finance its operations through debt and/or equity financing as needed."
• "Our officers have 35 years of sleep-industry experience, including having been employed at sleep industry companies."
• "Our officers invented our DeltaWave CPAP interface (the DeltaWave) as an innovative new device to treat patients with sleep apnea."
• "We believe that our DeltaWave is designed to effectively address the stubborn issues that continue to affect a patient's ability to comply with treatment."
• "Our goal is to develop sleep products for the treatment of OSA and capture 10% of the market in the next 24 months."
• "Our continued existence is dependent upon our ability to resolve our liquidity problems and increase profitability in our current business operations."

Industry Context

The company operates in the sleep apnea treatment market, specifically focusing on CPAP therapy interfaces. The filing highlights the industry-recognized issue of patient compliance with CPAP masks, citing a survey where 89% of patients prioritized mask comfort. The DeltaWave product is positioned as an innovative solution to improve comfort and compliance by addressing issues like breathing mechanics, claustrophobia, work of breathing, and sinus drying. The company's shift from its previous CPAP machine to the DeltaWave indicates a strategic focus on the interface component of therapy, aligning with the identified market need for better mask solutions.

Comparison to Industry Standards

• The company's stated goal of capturing 10% of the OSA market in the next 24 months is highly ambitious given its current revenue of $4,824 for the first half of 2025 and its ongoing 'going concern' issues. Major players in the CPAP market, such as ResMed and Philips Respironics (though Philips has faced recent recalls), have established global distribution networks, extensive R&D, and significant market share, making a 10% capture by REMSLEEP a challenging benchmark without substantial capital infusion and rapid scaling.
• The company's financial performance, characterized by recurring losses and negative cash flow from operations, falls significantly below the profitability and cash generation standards of established, publicly traded medical device companies in the respiratory or sleep therapy sector. For instance, ResMed (RMD) consistently reports strong revenue growth and positive net income, demonstrating a robust business model and market penetration that REMSLEEP currently lacks.
• While the FDA 510k approval for DeltaWave is a positive step, the company's ability to commercialize and scale production to compete with the manufacturing capabilities and supply chain efficiencies of larger competitors remains unproven. Companies like Fisher & Paykel Healthcare also have well-developed product lines and manufacturing capacities that set a high industry standard for product availability and cost-effectiveness.

Management Changes

Corporate Governance

Related Party Transactions

• Compensation expense of $51,000 paid to the CEO, Mr. Wood, for the six months ended June 30, 2025 (increased from $48,000 in 2024).
• Accrued compensation of $46,000 due to Russell Bird, the former Chairman, as of June 30, 2025.
• Cash payments of $7,000 made to Jonathan Lane, Chief Technology Officer, for the six months ended June 30, 2025.
• Payments of $20,000 made to the CEO's brother for services related to product development for the six months ended June 30, 2025.

Stakeholder Impact

• **Shareholders:** Face significant dilution risk from ongoing convertible debt conversions and potential future equity raises. The 'going concern' doubt poses a substantial risk to the value of their investment. The lack of effective disclosure controls also raises governance concerns.
• **Creditors (especially convertible note holders):** The company's precarious financial position and reliance on further financing increase credit risk. However, convertible note terms with discounts to market price offer potential for conversion into equity, albeit at the expense of existing shareholders.
• **Employees:** The company's financial instability and 'going concern' doubt could impact job security and future compensation, although compensation to the CEO and CTO is noted.
• **Customers:** The launch of the DeltaWave product, if successful, could offer an improved solution for sleep apnea patients. However, the company's financial health could impact long-term product support and availability.
• **Suppliers:** The company's liquidity issues and reliance on external financing could pose payment risks for suppliers, although no specific issues were noted in the filing.

Next Steps

• Obtain funding from new investors to alleviate working capital deficiency.
• Implement a plan to generate sales for the DeltaWave product.
• Conduct clinical trials to test DeltaWave product effectiveness, pending adequate financing.
• Continue to finance operations through debt and/or equity financing as needed.
• Address the identified ineffectiveness of disclosure controls and procedures due to lack of segregation of duties.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by a dramatic 94.4% decline in revenue, a substantial increase in liabilities, and an accumulated deficit exceeding $15 million. The explicit 'going concern' doubt from both management and auditors signals a high risk of insolvency. While the DeltaWave product received FDA approval, the company's inability to generate meaningful sales from it, coupled with its reliance on dilutive convertible debt for financing, indicates a highly unsustainable business model. The ineffective disclosure controls further compound governance concerns. Given the dire financial state and significant operational challenges, the stock presents an extremely high risk with little apparent upside potential, making it a strong sell for any seasoned investor or institution.

Keywords

Sleep Apnea, CPAP, DeltaWave, Medical Devices, Healthcare, Respiratory, SEC Filing, 10-Q, Financial Results, Going Concern, Convertible Debt, Product Development